Evicenter
P&T meetings

QTORIN rapamycin 3.9 percent gel

Microcystic lymphatic malformations

Regulatory submission
NDA submitted August 2026
Last updated
78 sources

Product information and disease descriptionPlace of product in therapyDisease description

Natural history, survival, and mortality

3 evidence topics · 3 sources

Natural history

“microcystic LMs are persistent and progressive and do not spontaneously regress.” (opens the source at this quote in a new tab)

Spontaneous regression: head and neck lymphatic malformations

“macrocystic composition emerged as the strongest possible predictor” (opens the source at this quote in a new tab)

Lymphatic malformations: complications affecting vital functions

“may cause serious complications that threaten vital functions such as compression of the airways.” (opens the source at this quote in a new tab)

Microcystic-specific survival and mortality estimates

No evidence found.